Exelixis | EXEL - 销售成本



金融业
股票价格
USD
资产
USD 2.59B
现金及等价物
USD 226.15M
销售成本
USD 19.95M
流动资产
USD 1.21B
流动负债
USD 370.98M
债务
USD 169.54M
EBIT
USD 251.34M
EBITDA
USD 258.29M
员工
1.15K
EPS每股收益
USD 0.87
股本和储备
USD 1.94B
销售毛利
USD 590.86M
债务利息支出
USD 23.4M
利息收入
USD 16.13M
市值
USD 15.89B
净收入
USD 210.47M
营业费用
USD 359.47M
营业利润
USD 251.34M
普通股股本
USD 253.7M
PE价格收益
13.91
税前利润
USD 267.69M
销售收入
USD 610.8M
销售和管理费用
USD 139.6M
股票
USD 26.61M
贸易债权人
USD 24.15M
应收帐款人
USD 328.95M


销售成本 更改 日
Acadia Pharmaceuticals USD 24.79M 1.43M 2026-03
Agios Pharmaceuticals USD 1.32M 560K 2026-03
Akebia Therapeutics USD 10.34M 441K 2025-12
Amgen USD 1.6B 187M 2026-03
AstraZeneca USD -204M 3.48B 2026-03
Bayer EUR 5.23B 731M 2026-03
BioMarin Pharmaceutical USD 199.48M 37.93M 2026-03
Bristol-Myers Squibb USD 3.86B 1.07B 2026-03
Cytokinetics USD 160K 104.24M 2026-03
Eisai JPY 52.02B 931M 2026-03
Eli Lilly USD 3.58B 205M 2026-03
Exelixis USD 19.95M 6.53M 2026-03
Genmab DKK 81M 23M 2025-12
Glaxosmithkline GBP 1.88B 1.6B 2026-03
Incyte USD 104.5M 16.68M 2026-03
Ionis Pharmaceuticals USD 3M 5M 2026-03
MacroGenics USD 9.53M 585K 2026-03
Merck USD 2.94B 380M 2026-03
Moderna USD 955M 503M 2026-03
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Neurocrine Biosciences USD 13.8M 3.8M 2026-03
Novartis USD 3.46B 83M 2026-03
Pfizer USD 4.59B 1.7B 2026-03
Puma Biotechnology USD 29.1M 18.44M 2024-09
Sanofi EUR 3.14B 618M 2026-03
Takeda JPY 560.54B 159.39B 2026-03
Ultragenyx Pharmaceutical USD 30M 1000K 2026-03
Xencor USD 61.66M 50.95M 2025-06